Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer

Spigel David R.; Patel Jyoti D.; Reynolds Craig H.; Garon Edward B.; Hermann Robert C.; Govindan Ramaswamy; Olsen Mark R.; Winfree Katherine B.; Chen Jian; Liu Jingyi; Guba Susan C.; Socinski Mark A.; Bonomi Philip

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer

【24h】

Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer

机译：生活质量分析来自于培美曲塞-卡铂-贝伐单抗，维持培美曲塞-贝伐单抗与紫杉醇-卡铂-贝伐单抗再继之维持贝伐单抗的培美曲塞-卡铂-贝伐单抗的随机，开放标签，III期PointBreak研究，分析了IIIB或IV期非鳞状非-S患者细胞肺癌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Treatment impact on quality of life (QoL) informs treatment management decisions in advanced nonsquamous non-small-cell lung cancer (NS NSCLC). QoL outcomes from the phase III PointBreak trial are reported.

机译：简介：治疗对生活质量（QoL）的影响为晚期非鳞状非小细胞肺癌（NS NSCLC）的治疗管理决策提供了依据。据报道，III期PointBreak试验的QoL结果。

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2015年第2期|共7页
作者
Spigel David R.; Patel Jyoti D.; Reynolds Craig H.; Garon Edward B.; Hermann Robert C.; Govindan Ramaswamy; Olsen Mark R.; Winfree Katherine B.; Chen Jian; Liu Jingyi; Guba Susan C.; Socinski Mark A.; Bonomi Philip;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Nonsquamous non-small-cell lung cancer; Pemetrexed; Bevacizumab; Functional assessment of cancer therapy; Paclitaxel;

机译：非鳞状非小细胞肺癌;培美曲塞;贝伐单抗;癌症治疗的功能评估;紫杉醇;
入库时间 2022-08-19 05:04:15

相似文献

外文文献
中文文献
专利

1. Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer [J] . Spigel David R., Patel Jyoti D., Reynolds Craig H., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第2期

机译：生活质量分析来自于培美曲塞-卡铂-贝伐单抗，维持培美曲塞-贝伐单抗与紫杉醇-卡铂-贝伐单抗再继之维持贝伐单抗的培美曲塞-卡铂-贝伐单抗的随机，开放标签，III期PointBreak研究，分析了IIIB或IV期非鳞状非-S患者细胞肺癌
2. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. [J] . Patel JD, Bonomi P, Socinski MA, Clinical lung cancer . 2009,第4期

机译：突破性研究的治疗原理和研究设计：培美曲塞/卡铂/贝伐单抗的随机，开放标签III期研究，然后进行培美曲塞/贝伐单抗与紫杉醇/卡铂/贝伐单抗的维持治疗，对IIIB或IV期非鳞状非IV期患者进行贝伐珠单抗治疗-小细胞肺癌。
3. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer [J] . Jyoti D. Patel, Mark A. Socinski, Edward B. Garon, Journal of Clinical Oncology . 2013,第34期

机译：PointBreak：培美曲塞加卡铂和贝伐单抗继之以维持治疗的随机III期研究ⅢB或IV期非鳞状非小细胞肺癌患者培美曲塞和贝伐单抗与紫杉醇加卡铂和贝伐单抗继之以贝伐单抗维持治疗
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Evaluation of Symptom Management in Patients with Advanced Stage (IIIB and IV) Non-Small Cell Lung Cancer [D] . Mann, LaTonya E. 2018

机译：晚期（IIIB和IV）非小细胞肺癌患者症状管理的评估
6. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer [O] . Jyoti D. Patel, Mark A. Socinski, Edward B. Garon, -1

机译：PointBreak：培美曲塞加卡铂和贝伐单抗继之维持治疗的随机III期研究ⅢB或IV期非鳞状非小细胞肺癌患者培美曲塞和贝伐单抗与紫杉醇加卡铂和贝伐珠单抗继之贝伐单抗维持治疗
7. Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer [O] . Spigel David R., Patel Jyoti D., Reynolds Craig H., 2015

机译：生活质量分析来自于培美曲塞-卡铂-贝伐单抗，维持培美曲塞-贝伐单抗与紫杉醇-卡铂-贝伐单抗再继之维持贝伐单抗的培美曲塞-卡铂-贝伐单抗的随机，开放标签，III期PointBreak研究，分析IIIB或IV期非鳞状非-S期患者细胞肺癌

摘要

著录项

相似文献

相关主题

期刊订阅